Skip to main content
  1. Right Decisions
  2. DGRefHelp - NHS Dumfries & Galloway
  3. Sexual health
  4. Back
  5. Contraception
  6. Contraception and Substance Misuse
Important: please update your RDS app to version 4.7.3 Details with newsletter below.

Please update your RDS app to v4.7.3

We asked you in January to update to v4.7.2.  After the deployment planned for 27th February, this new update will be needed to ensure that you are able to download RDS toolkits even when the RDS website is not available. We will wait until as many users as possible have downloaded the new version before switching off the old system for app downloads and moving entirely to the new approach.

To check your current RDS version, click on the three dots bottom right of the RDS app screen. This takes you to a “More” page where you will see the version number. 

To update to the latest release:

 On iPhones – go to the Apple store, click on your profile icon top right, scroll down to see the apps waiting to be updated and update the RDS app.

On Android phones – these can vary, but try going to the Google Play store, click on your profile icon top right, click on “Manage apps and device”, select and update the RDS app.

Right Decision Service newsletter: February 2025

Welcome to the February 2025 update from the RDS team

1.     Next release of RDS

 

A new release of RDS is planned (subject to outcomes of current testing) for week beginning 24th February. This will deliver:

 

  • Fixes to mitigate the recurring glitches with the RDS admin area and the occasional brief user interface outages which have arisen following implementation of the new distributed technology infrastructure in December 2024.

 

  • Capability to embed content from Google calendar, Google Maps, Daily Motion, Twitter feeds, Microsoft Stream into RDS pages.

 

  • Capability to include simple multiplication in RDS calculators.

 

The release will also incorporate a number of small fixes, including:

  • Exporting of form within Medicines Sick Day Guidance in polypharmacy toolkit
  • Links to redundant content appearing in search in some RDS toolkits
  • Inclusion of accordion headers alongside accordion text in search result snippets.
  • Feedback form on mobile app.
  • Internal links on mobile app version of benzo tapering tool

 

We will let you know when the date and time for the new release are confirmed.

 

2.     New RDS developments

There is now the capability to publish toolkits on the web with left hand side navigation rather than tiles on the homepage. To use this feature, turn on the “Toggle navigation panel” option at the top of the Page settings menu at toolkit homepage level – see below. Please note that publication to downloadable mobile app for this type of navigation is still under development.

The Benzodiazepine tapering tool (https://rightdecisions.scot.nhs.uk/benzotapering) is now available as part of the RDS toolkit for the national benzodiazepine prescribing guidance developed by the Scottish Government Effective Prescribing team. The tool uses this national guidance developed with a wide-ranging multidisciplinary group. This should be used in combination with professional judgement and an understanding of the needs of the individual patient.

3.     Archiving and version control and new RDS Search and Browse interface

Due to the intensive work Tactuum has had to undertake on the new technology infrastructure has pushed back the delivery dates again and some new requirements have come out of the recent user acceptance testing. It now looks likely to be an April release for the search and browse interface. The archiving and version control functionality may be released earlier. We’ll keep you posted.

4.     Statistics

At the end of January, Olivia completed the generation of the latest set of usage statistics for all RDS toolkits. If you would like a copy of the stats for your toolkit, please contact Olivia.graham@nhs.scot .

 

5.     Review of content past its review date

We have now generated reports of all RDS toolkit content that has exceeded its review date by 6 months or more. We will be in touch later this month with toolkit owners and editors to agree the plan for updating or withdrawing out of date content.

 

6.     Toolkits in development

Some important toolkits in development by the RDS team include:

  • National CVD prevention pathways – due for release end of March 2025.
  • National respiratory pathways, optimal cancer diagnostic pathways and cancer prehabilitation pathways from the Centre for Sustainable Delivery. We will shortly start work on the national cancer referral pathways, first version due for release via RDS around end of June 2025.
  • HIS Quality of Care Review toolkit – currently in final stages of quality assurance.

 

The RDS team and other information scientists in HIS have also been producing evidence summaries for the Scottish Government Realistic Medicine team, to inform development of national guidance around Procedures of Limited Clinical Value. This guidance will in due course be translated into an RDS toolkit.

 

7. Training sessions for new editors (also serve as refresher sessions for existing editors) will take place on the following dates:

  • Friday 28th February 12-1 pm
  • Tuesday 11th March 4-5 pm

 

To book a place, please contact Olivia.graham@nhs.scot, providing your name, organisation, job role, and level of experience with RDS editing (none, a little, moderate, extensive.)

 

To invite colleagues to sign up to receive this newsletter, please signpost them to the registration form  - also available in End-user and Provider sections of the RDS Learning and Support area.   If you have any questions about the content of this newsletter, please contact his.decisionsupport@nhs.scot  If you would prefer not to receive future newsletters, please email Olivia.graham@nhs.scot and ask to be removed from the circulation list.

With kind regards

 

Right Decision Service team

Healthcare Improvement Scotland

 

 

Contraception and Substance Misuse

Warning

Key Points

Clients affected by substance misuse may have difficulties prioritising their own healthcare and some will have difficulties adhering to some contraceptive methods and a LARC method is likely to be the most appropriate option.
For vulnerable clients, sharing information with relevant professionals, eg risk of pregnancy, cannot be emphasised strongly enough and this should be discussed with clients. They can be offered referral for preconception counselling and supported to involve their key worker/social worker in the event of a pregnancy.

Clients affected by drugs or alcohol who can consent to treatment, should be given the same care as any other client. Due to their sometimes fluctuating mental states it is especially important to ensure that, at the time of consent to treatment, they are fully aware of all the implications and that this is documented clearly. On rare occasions where a client appears to be incoherent, but has presented for advice, the case and management should be discussed with a senior colleague.

All patients should be offered regular sexual health testing ie HIV, syphilis, gonorrhoea and chlamydia. Some drug users may also require testing for hepatitis B & C and some may require vaccination for hepatitis B. There is currently an HIV outbreak amongst people who inject drugs (PWIDs) in Glasgow.

Individual Drugs And Contraception Considerations

Different drugs may pose different risks for those requiring contraception.

 

AMPHETAMINES, COCAINE
& ECSTASY
All have similar effects on the sympathetic nervous system and cardiovascular system causing acute arterial hypertension, vasospasm, thrombosis and accelerated atherosclerosis. In view of this it would be sensible to avoid oestrogen-containing contraceptives.
BENZODIAZEPINES  No specific cautions apply but as misusers of these often misuse other substances, a careful drugs history should be taken.
HEROIN Women who are injecting drug users, who have a history of thrombosis, or have liver impairment secondary to hepatitis C (or alcohol), should not be offered oestrogen containing contraceptives.
Women who smoke heroin can use all types of contraception if there are no other contraindications. As these women often progress to injecting, careful follow up is necessary and non oestrogen methods especially LARC should be considered.
METHADONE

Most women on methadone will have been injecting drug users and some may continue to inject, even when on methadone. It may,therefore, be prudent to avoid oestrogen.
Women who have not been injecting drug users and therefore at low risk of hepatitis C or VTE can be offered all types of contraception provided there are no other contraindications. Opiates can inhibit ovulation: the effect is dose dependent and unpredictable so effective contraception is required even in the presence of amenorrhoea.

EXCESSIVE ALCOHOL DRINKERS Most will have fatty livers. (see below)

Specific Medical Issues In Women Who Have Drug and / or Alcohol Problems

  1. Hepatitis C
    If a client is known to have hepatitis C, it is useful to know whether she has attended specialist services. She is likely to know if her disease is active or has resolved.
    Checking LFTs may guide your choice of contraception but should not delay it as the client may not return. For women on treatment for hepatitis C it is essential to ensure effective contraception as RIBAVIRIN is teratogenic. Effective contraception should be used while on Ribavirin and continued after completing the treatment for 4 months for females, 7 months for males.For hepatitis patients the use of Nexplanon, and IUS or IUD is recommended.
    Oestrogen-containing methods are UKMEC 3/4 (likely unacceptable health risks) for initiation and UKMEC 2 for continuation for women with active viral hepatitis. For women with stable disease and normal liver function these methods can be considered UKMEC 1.
    Progestogen-only methods are UKMEC 1 for women with active viral hepatitis.                         
  2. Venothromboembolism
    Women who inject drugs are at risk of VTE as the drugs they inject are usually cut with various impurities which can cause vascular damage in addition to repeated trauma. Oestrogen containing contraceptives should be avoided if a woman has a history of VTE (UKMEC 4) or is an injecting drug user. All progestogen methods are UKMEC 2 and so can be used.                                                                                                                                              
  3. Fatty Liver and Cirrhosis
    Fatty Liver is a reversible stage of alcoholic liver disease and resolves when alcohol intake decreases. Alcoholic hepatitis will occur (in 20-30%) if drinking continues to excess; about 10% of patients develop cirrhosis with continued drinking. For women who have mild cirrhosis without complication, all methods can be considered UKMEC 1.For women with severe decompensated cirrhosis, oestrogen methods should be avoided (UKMEC 4).Progestogen only methods can be considered after expert review (UKMEC 3). Copper IUD is UKMEC 1.

References

Scottish Drug Services Directory
http://www.scottishdrugservices.com/

FSRH. UK Medical eligibility criteria for contraceptive use. July 2016.
UKMEC (pagelizard.com)

Editorial Information

Last reviewed: 31/05/2022

Next review date: 01/01/2025

Author(s): West of Scotland Managed Clinical Network for Sexual Health Clinical Guidelines Group.

Version: 2.1

Approved By: West of Scotland Managed Clinical Network for Sexual Health